Home » Stocks » AXGN

Axogen, Inc. (AXGN)

Stock Price: $20.20 USD 0.14 (0.70%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 813.10M
Revenue (ttm) 119.08M
Net Income (ttm) -22.25M
Shares Out 41.00M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $20.20
Previous Close $20.06
Change ($) 0.14
Change (%) 0.70%
Day's Open 20.18
Day's Range 20.01 - 20.43
Day's Volume 56,584
52-Week Range 10.42 - 23.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to per...

1 week ago - GlobeNewsWire

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

1 week ago - GlobeNewsWire

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...

2 weeks ago - GlobeNewsWire

Axogen Inc (NASDAQ: AXGN) has announced to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, pending ongoing discussions with the FDA regarding the regulatory class...

2 months ago - Benzinga

ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peri...

2 months ago - GlobeNewsWire

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

2 months ago - Zacks Investment Research

ALACHUA, Fla. and TAMPA, Fla. , May 06, 2021 (GLOBE NEWSWIRE) --  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to pe...

2 months ago - GlobeNewsWire

AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat...

2 months ago - Benzinga

ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, toda...

2 months ago - GlobeNewsWire

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...

3 months ago - GlobeNewsWire

ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced th...

4 months ago - GlobeNewsWire

ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fina...

5 months ago - GlobeNewsWire

ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, ...

5 months ago - GlobeNewsWire

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the benc...

Other stocks mentioned: MATX, WK
6 months ago - GuruFocus

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerv...

6 months ago - GlobeNewsWire

ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, an...

7 months ago - GlobeNewsWire

AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement

7 months ago - Seeking Alpha

ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, to...

8 months ago - GlobeNewsWire

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fina...

9 months ago - GlobeNewsWire

ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, to...

9 months ago - GlobeNewsWire

COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.

9 months ago - Seeking Alpha

Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors

9 months ago - GlobeNewsWire

ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerve...

10 months ago - GlobeNewsWire

New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft

10 months ago - GlobeNewsWire

ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves...

10 months ago - GlobeNewsWire

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves...

1 year ago - GlobeNewsWire

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Av...

1 year ago - GlobeNewsWire

ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, ...

1 year ago - GlobeNewsWire

ALACHUA, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a...

1 year ago - GlobeNewsWire

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October Freitag will continue as member of board of directors and serve as special counsel...

1 year ago - GlobeNewsWire

ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves,...

1 year ago - GlobeNewsWire

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced ...

1 year ago - GlobeNewsWire

ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerve...

1 year ago - GlobeNewsWire

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries Largest peripheral nerve repair registry in the world...

1 year ago - GlobeNewsWire

AxoGen Working Its Way Out Of The Penalty Box, But Execution Is Key

1 year ago - Seeking Alpha

Company will develop an automated bioprocessing system for human tissue scaffolds

1 year ago - GlobeNewsWire

Parade float will highlight the life-changing power of tissue and organ donation Parade float will highlight the life-changing power of tissue and organ donation

1 year ago - GlobeNewsWire

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM... [Read more...]

Industry
Medical Devices
Stock Exchange
NASDAQ
Ticker Symbol
AXGN
Full Company Profile

Financial Performance

In 2020, Axogen's revenue was $112.30 million, an increase of 5.24% compared to the previous year's $106.71 million. Losses were -$23.79 million, -18.36% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Axogen stock is "Buy." The 12-month stock price forecast is 26.17, which is an increase of 29.55% from the latest price.

Price Target
$26.17
(29.55% upside)
Analyst Consensus: Buy